Annual report pursuant to Section 13 and 15(d)

Consolidated Statement of Changes in Stockholders' Equity

v3.19.1
Consolidated Statement of Changes in Stockholders' Equity - USD ($)
Common Stock [Member]
Preferred Stock [Member]
Additional Paid-In Capital [Member]
Subscription Receivable [Member]
Accumulated Deficit [Member]
Total
Balance at Dec. 31, 2016 $ 3,175 $ 4,266,825 $ (2,002,772) $ (2,267,229)
Balance, shares at Dec. 31, 2016 31,745,242        
Fair value of Heatwurx net liabilities obtained in a reverse merger $ 352 (38,102) (37,750)
Fair value of Heatwurx net liabilities obtained in a reverse merger, shares 3,527,284        
Net loss (1,856,315) (1,856,315)
Balance at Dec. 31, 2017 $ 3,527 4,228,723 (3,859,087) 373,164
Balance, shares at Dec. 31, 2017 35,272,626        
Recognize the fair value of the license acquired from CoNCERT in exchange for 2,090,301 common shares of Processa 8,000,000 8,000,000
Conversion of senior convertible notes and accrued interest for common stock and stock purchase warrants, net of costs of $82,502 $ 121 2,312,488 2,312,609
Conversion of senior convertible notes and accrued interest for common stock and stock purchase warrants, net of costs of $82,502, shares 1,206,245        
Issuance of common stock units for cash, net of costs of $308,830 $ 140 2,874,547 2,874,687
Issuance of common stock units for cash, net of costs of $308,830, shares 1,402,442        
Issuance of common stock units for a clinical trial funding commitment, net of costs of $168,457 $ 79 1,631,464 (1,800,000) (168,457)
Issuance of common stock units for a clinical trial funding commitment, net of costs of $168,457, shares 792,952        
Stock-based compensation 74,063 74,063
Net loss (3,765,047) (3,765,047)
Balance at Dec. 31, 2018 $ 3,867 $ 19,121,285 $ (1,800,000) $ (7,624,134) $ 9,701,018
Balance, shares at Dec. 31, 2018 38,674,265